Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, and Asia.
+ 2 more risks
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Epigenomics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ECX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ECX underperformed the German Biotechs industry which returned -13.5% over the past year.
Return vs Market: ECX underperformed the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is Epigenomics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
8 months ago | Simply Wall StIs Epigenomics AG (FRA:ECX) Excessively Paying Its CEO?
9 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The Epigenomics AG's (FRA:ECX) Shareholder Register?
11 months ago | Simply Wall StIf You Had Bought Epigenomics (FRA:ECX) Stock Three Years Ago, You'd Be Sitting On A 63% Loss, Today
Is Epigenomics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ECX (€1.01) is trading below our estimate of fair value (€4.05)
Significantly Below Fair Value: ECX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ECX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ECX is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ECX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ECX is overvalued based on its PB Ratio (4.1x) compared to the DE Biotechs industry average (3.3x).
How is Epigenomics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ECX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ECX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ECX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ECX's revenue (59.5% per year) is forecast to grow faster than the German market (4% per year).
High Growth Revenue: ECX's revenue (59.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ECX's Return on Equity is forecast to be high in 3 years time
How has Epigenomics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ECX is currently unprofitable.
Growing Profit Margin: ECX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ECX is unprofitable, and losses have increased over the past 5 years at a rate of -7.2% per year.
Accelerating Growth: Unable to compare ECX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ECX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: ECX has a negative Return on Equity (-156.36%), as it is currently unprofitable.
How is Epigenomics's financial position?
Financial Position Analysis
Short Term Liabilities: ECX's short term assets (€7.7M) exceed its short term liabilities (€3.2M).
Long Term Liabilities: ECX's short term assets (€7.7M) exceed its long term liabilities (€806.0K).
Debt to Equity History and Analysis
Debt Level: ECX is debt free.
Reducing Debt: ECX has no debt compared to 5 years ago when its debt to equity ratio was 73.4%.
Inventory Level: ECX has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if ECX's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ECX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ECX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -10.8% each year
What is Epigenomics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ECX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ECX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ECX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ECX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ECX's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Greg Hamilton (49yo)
Mr. Gregory Hamilton, also known as Greg, has been the Chief Executive Officer and Member of Executive Board at Epigenomics AG since July 1, 2016. Mr. Hamilton has over 20 years of management experience in ...
CEO Compensation Analysis
Compensation vs Market: Greg's total compensation ($USD1.04M) is above average for companies of similar size in the German market ($USD428.66K).
Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.
|CEO & Member of the Executive Board||3.75yrs||€962.25k||0.0053% €2.6k|
|Executive VP of Finance & Member of the Executive Board||2.25yrs||€422.01k||0.00021% €101.9|
|Vice President of Corporate Communications & Investor Relations||no data||no data||no data|
|Chief Executive Officer of Epigenomics Inc.||8.92yrs||no data||no data|
|Investor Relations Officer||no data||no data||no data|
Experienced Management: ECX's management team is considered experienced (3 years average tenure).
|Deputy Chairwoman of the Supervisory Board||7.92yrs||€52.00k||0.13% €64.9k|
|Vice-Chairman of the Supervisory Board||5.42yrs||€52.00k||no data|
|Chairman of the Supervisory Board||7.92yrs||€102.00k||0.52% €252.3k|
|Member of the Supervisory Board||3.92yrs||€47.00k||0.013% €6.2k|
|Member of the Supervisory Board||0.92yr||no data||no data|
Experienced Board: ECX's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 50%.
Epigenomics AG's company bio, employee growth, exchange listings and data sources
- Name: Epigenomics AG
- Ticker: ECX
- Exchange: DB
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €48.544m
- Shares outstanding: 47.13m
- Website: https://www.epigenomics.com
Number of Employees
- Epigenomics AG
- Geneststrasse 5
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EPGN.F||OTCPK (Pink Sheets LLC)||Common Shares||US||USD||Jul 2004|
|EPGN.Y||OTCPK (Pink Sheets LLC)||SPONSORED ADR||US||USD||Jul 2013|
|ECX||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Sep 2014|
|ECX||XTRA (XETRA Trading Platform)||Yes||Registered Shares||DE||EUR||Sep 2014|
|0QXH||LSE (London Stock Exchange)||Yes||Registered Shares||GB||EUR||Sep 2014|
|ECXD||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Registered Shares||GB||EUR||Sep 2014|
|ECX||ETLX (Eurotlx)||Yes||Registered Shares||IT||EUR||Sep 2014|
Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, and Asia. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool provides set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of colorectal and lung cancers. In addition, the company engages in the research and identification of additional DNA methylation biomarkers for prostate, bladder, breast, and ovarian cancers. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/07 00:03|
|End of Day Share Price||2020/04/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.